UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CONSTELLATION ACQUISITION CORP I (Exact name of registrant as specified in its charter) Cayman Islands 98-1574835 (State or other jurisdiction of incorporation or organization) 200 Park Avenue 32nd Fl ...

Revenue Performance - Total revenues for the three months ended March 31, 2025, were $48.317 million, an increase of 3.2% from $46.823 million in the same period of 2024[42] - The Data and Analytics Services segment generated $8.960 million in revenue for the three months ended March 31, 2025, up 11.1% from $8.067 million in 2024[42] - The IT Staffing Services segment reported revenue of $39.357 million for the three months ended March 31, 2025, compared to $38.756 million in 2024, reflecting a growth of 1.5%[42] - Revenue from the United States was $47.752 million for the three months ended March 31, 2025, compared to $46.116 million in 2024[44] - Revenues for Q1 2025 totaled $48.3 million, a 3% increase from $46.8 million in Q1 2024, driven by 11% growth in Data and Analytics Services and 2% growth in IT Staffing Services[103] Client Concentration - The top ten clients accounted for approximately 56% of total revenues in Q1 2025, compared to 51% in Q1 2024[43] - The company’s revenues are highly concentrated among a limited number of clients, which may impact operational results[100] Profitability and Expenses - Gross profit for Data and Analytics Services was $3,947,000 in Q1 2025, compared to $3,745,000 in Q1 2024, resulting in a gross margin of 44.1%[83] - Total gross profit increased to $12,892,000 in Q1 2025 from $12,131,000 in Q1 2024, with a total gross margin of 26.7%[83] - SG&A expenses increased to $14.7 million in Q1 2025, representing 30.4% of total revenues, compared to $12.5 million or 26.7% in Q1 2024[109] - Stock-based compensation expense for Q1 2025 was $895,000, up 62.73% from $550,000 in Q1 2024[61] Goodwill and Impairment - Goodwill related to the IT Staffing Services segment remained unchanged at $8.427 million as of March 31, 2025[47] - The Company recorded a goodwill impairment of $5.3 million related to the Data and Analytics Services segment in 2023[45] Tax and Losses - The Company reported a loss before income taxes of $1,762,000 for Q1 2025, compared to a loss of $282,000 in Q1 2024[73] - The total provision for income taxes for Q1 2025 was a benefit of $323,000, compared to a benefit of $121,000 in Q1 2024[74] - The company reported an effective tax benefit of ($323,000) for Q1 2025, compared to ($121,000) in Q1 2024, reflecting a significant change in tax strategy[113] Cash Flow and Assets - Cash used in operating activities for Q1 2025 was ($3.0 million), compared to ($1.3 million) in Q1 2024, with a net loss of ($1.4 million) in 2025[117] - As of March 31, 2025, the company had cash balances of $24.7 million and no bank debt outstanding, with $23.7 million of borrowing capacity available[114] - Total assets decreased to $110,076,000 as of March 31, 2025, from $111,484,000 as of December 31, 2024[84] Future Outlook and Costs - The company expects to incur additional costs of $500,000 to $750,000 during the transition of finance and accounting functions to India, with anticipated annual savings of approximately $1,200,000 post-transition[94] - Economic conditions in North America improved in 2024, but uncertainty remains for 2025 due to potential changes in administration policies[99] Stock Incentive Plans - The Company granted 22,140 restricted share units and 702,358 stock options at a strike price of $15.41 during Q1 2025[60] - As of March 31, 2025, there were 430,000 shares available for grant under the Stock Incentive Plan and 798,000 shares under the 2024 Inducement Stock Incentive Plan[60] - The 2024 Inducement Stock Incentive Plan was terminated effective May 14, 2025, ceasing further grants under this plan[60] - The Company has 432,059 shares available for purchase under the Employee Stock Purchase Plan as of March 31, 2025[65] New Business and Demand - New bookings in Q1 2025 totaled $11.7 million, up from $9.6 million in Q1 2024, indicating strong demand for services[104]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to ___________ Commission file number: 001-41265 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 47-4828381 (State of Incorporation) (IRS E ...

Financial Performance - Total interest income for Q1 2025 was $8,367,000, a decrease of 2.8% from $8,609,000 in Q1 2024[13] - Net interest income after provision for credit losses was $5,417,000, slightly down from $5,485,000 in the same period last year[13] - Non-interest income increased to $724,000 in Q1 2025, up from $707,000 in Q1 2024, representing a growth of 2.4%[13] - Net income for Q1 2025 was $1,057,000, compared to $1,014,000 in Q1 2024, reflecting a growth of 4.2%[13] - Basic and diluted earnings per share increased to $0.19 in Q1 2025, up from $0.17 in Q1 2024[13] - Total comprehensive income for Q1 2025 was $1,070,000, significantly higher than $216,000 in Q1 2024[14] - Other Comprehensive Income for Q1 2025 was $13,000, a significant recovery from a loss of $798,000 in Q1 2024[14] Expenses and Dividends - Total non-interest expense decreased to $4,878,000 in Q1 2025, down from $4,995,000 in Q1 2024, a reduction of 2.4%[13] - Cash dividends declared per share were $0.18 in Q1 2025, compared to no dividends declared in Q1 2024[13] Credit Losses and Provisions - The provision for credit losses was $48,000 in Q1 2025, a reversal from a credit loss of $352,000 in Q1 2024[13] - The allowance for credit losses increased by $37,000 for loans and $9,000 for unfunded commitments as of March 31, 2025, compared to December 31, 2024[30] - The provision for credit losses for the three months ended March 31, 2025, was $39 thousand, while for the same period in 2024, it was a negative $223 thousand, indicating a significant shift in credit quality assessment[55] - The total allowance for credit losses on loans was $5,170 thousand as of March 31, 2025, compared to $6,463 thousand on March 31, 2024, reflecting a decrease of about 20%[55] Loans and Deposits - Net increase in deposits was $9,752,000, up from $3,780,000 in the previous year[18] - As of March 31, 2025, the company's total gross loans amounted to $553.6 million, an increase from $546.5 million as of December 31, 2024, representing a growth of approximately 1.9%[45] - The company's real estate loans totaled $528.7 million as of March 31, 2025, slightly down from $529.8 million as of December 31, 2024, indicating a decrease of about 0.2%[45] - The total gross loans receivable as of March 31, 2025, was $553,631,000, showing a slight increase from $546,490,000 as of December 31, 2024[61] Cash Flow and Investments - Net cash provided by operating activities was $718,000, compared to a net cash used of $32,000 in the prior year[18] - The company reported a net cash used in investing activities of $5,601,000, a significant decrease from $8,411,000 in the same period of 2024[18] - Cash and cash equivalents at the end of the period were $30,428,000, down from $54,953,000 at the end of the same period in 2024[18] - Interest paid during the period was $2,918,000, a decrease from $3,979,000 in the prior year[18] Securities and Fair Value - Total debt securities available for sale had a fair value of $55,681,000, with unrealized losses of $12,620,000[36] - The estimated fair value of total securities as of March 31, 2025, was $55,801,000, compared to $56,495,000 as of December 31, 2024[98] - The fair value of municipal bonds pledged as collateral for customer deposits was $3.8 million as of March 31, 2025, down from $4.6 million as of December 31, 2024[39] - The company recognized an unrealized gain of $46,000 on equity securities during the three months ended March 31, 2025, compared to an unrealized gain of $11,000 during the same period in 2024[44] Stock and Compensation - Stock-based compensation costs for the three months ended March 31, 2025, were $120,000, compared to $38,000 for the same period in 2024[80] - The 2025 Equity Incentive Plan was approved on February 4, 2025, allowing for the issuance of up to 300,000 shares of common stock[88] - A total of 27,197 restricted stock awards were granted under the 2025 EIP at a fair value of $15.77 per share[89] - The ESOP compensation expense was $31,000 for the three months ended March 31, 2025, compared to $23,000 for the same period in 2024[91] Credit Quality and Loan Classification - The company classified its loans into categories such as Pass, Special Mention, Substandard, Doubtful, and Loss, with a focus on monitoring credit quality indicators monthly[65][67] - The total gross loans classified as Pass for residential, one- to four-family loans was $156,198,000 as of March 31, 2025[68] - Non-accrual loans totaled $3,804 thousand as of March 31, 2025, compared to $3,472 thousand on December 31, 2024, marking an increase of approximately 9.5%[60] Miscellaneous - The company is transitioning to a fully-public stock holding company structure, with the SEC declaring the New Bank Holding Company's Registration Statement effective on May 14, 2025[32] - The company had no foreclosed real estate as of March 31, 2025, and December 31, 2024[75] - The company did not sell any debt securities during the three months ended March 31, 2025, and 2024[43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35922 PEDEVCO Corp. (Exact name of registrant as specified in its charter) Texas 22-3755993 (State or other jurisdiction of incor ...

Table of Contents ppju5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 OR ☐ Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-41052 Tivic Health Systems, Inc. (Exact name of registrant as specified in its charter) Delaware (St ...

Financial Results - KULR Technology Group, Inc. announced financial results for Q1 2025, with specific figures to be detailed in the press release[5] - The financial results and operational highlights are expected to provide insights into the company's performance and future strategies[10] - The press release is attached as Exhibit 99.1, which contains detailed financial data[11] Company Information - The company is listed on NYSE American LLC under the trading symbol KULR[3] - The company has not indicated whether it is an emerging growth company in this filing[4] Reporting and Compliance - The report is filed under Form 8-K, which is a current report for significant events[1] - The CEO, Michael Mo, signed the report, affirming the authenticity of the information provided[15] Communication and Disclosure - The company utilizes various social media channels for public disclosures, enhancing investor communication[9] - The press release includes operational highlights alongside the financial results, indicating a focus on recent developments[7] Timeliness - The date of the report is May 15, 2025, indicating the timeliness of the information[2]

Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-May 15, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune ce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report: _____________ For the transition period from ______ to ________ Commission file number: 001-4 ...

Financial Performance - Total revenue for the three months ended March 31, 2025, was $1,708,000, an increase of 12.7% compared to $1,516,000 for the same period in 2024[17] - The net loss attributable to common stockholders for the three months ended March 31, 2025, was $3,615,000, compared to a net income of $17,169,000 for the same period in 2024[17] - The company reported a total comprehensive loss of $8,007,000 for the three months ended March 31, 2025, compared to a comprehensive income of $114,028,000 for the same period in 2024[17] - The company reported a share of loss from equity method investments of $4.1 million for the three months ended March 31, 2025, compared to income of $1.2 million for the same period in 2024[55] - The Company reported a net loss before taxes of $8,093 million for the three months ended March 31, 2025, compared to a net income of $114,023 million for the same period in 2024[89] Operating Expenses - Operating expenses for the same period were $8,047,000, up from $6,829,000, reflecting a 17.8% increase year-over-year[17] - The company reported a loss from operations of $6,339,000 for the three months ended March 31, 2025, compared to a loss of $5,313,000 in the prior year[17] - Selling, general and administrative expenses decreased by $0.5 million to $6.3 million for the three months ended March 31, 2025, primarily due to a $1.8 million decrease in audit and professional service fees[120] - Research and development expenses for the three months ended March 31, 2025, were $118 million, while there were no expenses reported for the same period in 2024[89] - Research and development expenses increased to $0.1 million for the three months ended March 31, 2025, compared to $16 thousand for the same period in 2024, primarily due to the development of a location-based entertainment experience[122] Cash and Liquidity - Cash and cash equivalents at the end of the period were $1,108,000, an increase from $1,050,000 at the end of March 31, 2024[19] - The Company reported cash provided by operating activities of $0.9 million for the three months ended March 31, 2025, compared to cash used of $(3.8) million for the same period in 2024, representing a $4.7 million improvement[157] - Cash used in investing activities was $(0.1) million for the three months ended March 31, 2025, a decrease from $(2.1) million in the same period of 2024, primarily due to reduced advances to unconsolidated joint ventures[158] - Net cash used by financing activities increased to $(0.6) million in the three months ended March 31, 2025, compared to cash provided of $6.2 million in the same period of 2024, mainly due to a $5.2 million decrease in net proceeds from related party loans[159] Assets and Liabilities - Total current assets decreased to $2,656,000 as of March 31, 2025, down from $4,134,000 as of December 31, 2024[15] - Total liabilities increased to $82,667,000 as of March 31, 2025, compared to $81,328,000 as of December 31, 2024[15] - The company has a working capital deficiency of $(39.1) million, excluding $10.4 million of debt maturing in the next 12 months as of March 31, 2025[35] - Total accrued expenses and other current liabilities increased to $32.2 million as of March 31, 2025, from $25.9 million as of December 31, 2024[59] - As of March 31, 2025, the company's total long-term debt amounted to $30.565 million, down from $30.977 million as of December 31, 2024, reflecting a decrease of approximately 1.3%[60] Revenue Concentration - The company reported significant revenue concentration in the Falcon's Creative Group segment, with QIC generating revenues of $5.9 million for the three months ended March 31, 2025, compared to $14.7 million for the same period in 2024[39] - The Company had one customer contributing $1.6 million, representing 95% of total revenue for Q1 2025, compared to $1.5 million or 100% for Q1 2024[40] - Accounts receivable from this customer totaled $0.3 million, accounting for 52% of total accounts receivable as of March 31, 2025[41] Financing and Investments - The company is reliant on stockholders and third parties to obtain additional financing through debt or equity raises to fund its working capital needs and expansion plans[35] - The company has committed to fund its share of additional investment in Karnival TP-AQ Holdings Limited for constructing Vquarium Entertainment Centers in China[34] - The Company has committed to funding non-interest-bearing advances of $9.0 million to the Karnival joint venture, with $6.6 million funded as of March 31, 2025[53] - The Company received net cash proceeds of $0.9 million from the Business Combination, net of $1.3 million in transaction costs related to FAST II and $1.6 million for Falcon's Opco[152] Business Operations - The company operates through three business divisions: Falcon's Creative Group, Falcon's Beyond Destinations, and Falcon's Beyond Brands, which are designed to accelerate growth[26] - The company aims to expand its physical operations and develop new product offerings as part of its growth strategy[33] - FCG recognized $4.7 million in revenue from a Dragon Ball theme park consultancy agreement during the three months ended March 31, 2025[132] - FCG anticipates that its capital expenditures and working capital requirements will increase materially in the near future[149] Internal Controls and Compliance - The Company has identified material weaknesses in its internal control over financial reporting as of March 31, 2025, and is implementing measures to improve these controls[161] - The Company has engaged third-party consulting firms to enhance its risk assessment and financial reporting processes as part of its remediation efforts[163]